Search the Newsreel

Xencor (NASDAQ: XNCR) to receive $105M, ending U.S. Ultomiris royalties

Xencor, Inc. has settled a commercial dispute with Alexion Pharma International Operations Limited regarding U.S. royalties on Ultomiris, agreeing to receive $105 million in two equal payments. This settlement concludes Alexion's obligation to pay U.S. royalties, while ex-U.S. royalties remain unaffected. The influx of …

Xencor stock hits 52-week high at 21.34 USD

Xencor Inc. (XNCR) stock reached a 52-week high of $21.34, trading at $21.40, marking a significant recovery from its $6.92 low and reflecting a 154.93% surge over the past year. This growth is attributed to investor confidence in its innovative pipeline of engineered monoclonal …

Xencor Reaches $105 Million Ultomiris Royalty Settlement With Alexion; U.S. Royalties End

Xencor has settled a dispute with Alexion over U.S. royalties for Ultomiris, securing a $105 million payment. This settlement, to be paid in two installments, concludes Alexion's obligation for U.S. sales royalties, though ex-U.S. royalties will continue. The agreement became effective on July 29, …

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

Xencor, Inc. announced an agreement with Alexion Pharma International Operations Limited to resolve a commercial dispute regarding U.S. royalties for Ultomiris. Xencor will receive $105 million in two equal payments, removing Alexion's future obligation for U.S. royalties while ex-U.S. royalties remain unchanged. This resolution …

Xencor (XNCR) Expected to Post Earnings on Wednesday

Xencor (XNCR) is set to release its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts forecasting a loss of $0.84 per share and revenue of $18.8890 million. The company significantly missed prior quarter estimates, reporting a $1.71 loss per share …

Xencor Inc (XNCR) Institutional Confidence

Xencor Inc (XNCR) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The overall institutional shareholding proportion decreased by 6.84% quarter-over-quarter to 119.03%. ETHSX is the largest institutional shareholder, holding 0.75% of outstanding shares, despite a …

Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xencor Inc (XNCR), detailing its current valuation score of 6.68, which ranks it 288 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.70 and notes that relevant data …

Xencor Inc (XNCR) Cash Flow

This article presents the detailed cash flow statements for Xencor Inc (XNCR), breaking down operating, investing, and financing activities across various quarterly and annual periods. It includes financial figures for net income, capital expenditures, and changes in working capital, allowing users to analyze the …

Xencor Inc (XNCR) Income Statement

This article presents the quarterly and annual income statements for Xencor Inc (XNCR), offering detailed financial data from FY2012Q4 to FY2026Q1, including total revenue, operating expenses, net income, and earnings per share. It allows users to analyze the company's financial performance and operational efficiency …

Xencor Inc (XNCR) Balance Sheet

This article provides Xencor Inc's (XNCR) balance sheet data, allowing users to evaluate the company's financial health, fundamentals, and key ratios. It includes quarterly financial data for assets, liabilities, and shareholders' equity, along with an FAQ section explaining key balance sheet metrics and their …

Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Xencor Inc's (XNCR) shareholder structure, listing major institutional holders and their percentage of ownership. It also categorizes shareholders by type and presents a history of institutional shareholdings and recent activity. Additionally, the article lists various ETFs that …

XNCR|Xencor Inc|Price:22.739|Chg%:-0.251

XNCR|Xencor Inc|Price:21.635|Chg%:+0.825

ETFs Investing in Xencor, Inc. Stocks

This article provides a comprehensive list of ETFs that hold Xencor, Inc. (XNCR) stocks, detailing information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The information presented aims to assist investors …

Xencor, Inc. Revenue Breakdown – DUS:XE9

Xencor, Inc. (DUS:XE9) generated 106.92 million EUR last year, primarily from its Engineered Antibody Therapeutics segment, marking a slight increase from the previous year. The company's revenue largely originated from the United States. This report provides a breakdown of the company's top segments and …

Xencor, Inc. (XNCR) Stock Forecasts

Xencor Inc. (XNCR) received a rating increase to "HOLD" from Argus on July 22, 2026. The clinical-stage biopharmaceutical company focuses on developing engineered antibody therapeutics for cancer and autoimmune diseases. Currently, its stock price is $19.54.

Wedbush Reaffirms Their Buy Rating on Xencor (XNCR)

(XNCR) Movement as an Input in Quant Signal Sets

Xencor Inc. (NASDAQ: XNCR) is showing strong sentiment across all horizons, supporting an overweight bias according to quantitative analysis. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each tailored to …

Xencor (XNCR) Updates Its Pipeline, Is The Stock Still Cheap?

Xencor (XNCR) recently updated its pipeline with positive phase I data for XmAb819 and progress on other candidates, leading to significant short-term share price momentum. Despite this, Simply Wall St's analysis suggests the stock is 28.2% undervalued, with a fair value of $28.50 compared …

Xencor stock hits 52-week high at 18.83 USD By Investing.com

Xencor Inc.'s stock reached a 52-week high of $18.85, boosting its market capitalization to $1.37 billion, reflecting a 102.97% increase over the past year due to investor optimism and drug development advancements. Despite this, InvestingPro analysis suggests the stock might be overvalued. Separately, Xencor …

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor (XNCR) shares surged 16.9% in the last trading session, driven by optimism regarding the progress of its oncology and autoimmune disease pipeline. Key developments include advancements in its lead oncology candidate XmAb819 and progress in immunology with XmAb942. Despite this, the company anticipates …

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. announced that results from its Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC) have been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail expansion-cohort results evaluating intravenous doses for the recommended …

Is Xencor (XNCR) Quietly Recasting Its Platform As A Solid-Tumor Oncology Story?

Xencor's antibody engineering platform is expanding into solid-tumor oncology, as evidenced by the upcoming oral presentation of XmAb819 Phase 1 results at the 2026 ESMO Congress and planned pivotal trial. This strategic shift complements ongoing progress in their TL1A programs, indicating a stronger focus …

Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026

Xencor plans to present Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma at ESMO 2026 in an oral presentation. The abstract will be released on October 18, with the full presentation occurring between October 23-27 in Madrid. These results are …

XNCR Forecast — Price Target — Prediction for 2027

These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts

Xencor Reports Massive 82% Revenue Growth as 4 Key Drug Candidates Progress in Clinical Trials